E Fund Management Co. Ltd. Acquires New Holdings in DexCom, Inc. $DXCM

E Fund Management Co. Ltd. bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, Holdings Channel.com reports. The firm bought 18,894 shares of the medical device company’s stock, valued at approximately $1,273,000.

Other institutional investors have also recently made changes to their positions in the company. Reflection Asset Management bought a new stake in DexCom during the fourth quarter valued at about $25,000. Ascentis Independent Advisors bought a new position in shares of DexCom during the 1st quarter valued at approximately $25,000. MCF Advisors LLC purchased a new position in shares of DexCom in the 4th quarter worth $32,000. Wellington Grp LLC grew its position in DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after acquiring an additional 475 shares in the last quarter. Finally, DV Equities LLC purchased a new position in shares of DexCom in the 4th quarter worth approximately $36,000. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on DXCM shares. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Monday, August 3rd. Truist Financial set a $93.00 price target on DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Benchmark increased their target price on shares of DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on DexCom in a research note on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $88.71.

Insiders Place Their Bets

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the transaction, the director directly owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the sale, the insider directly owned 328,970 shares in the company, valued at approximately $25,106,990.40. This trade represents a 7.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 73,035 shares of company stock worth $5,446,673. 0.28% of the stock is owned by company insiders.

DexCom Stock Up 0.3%

DexCom stock opened at $89.88 on Thursday. The stock’s fifty day simple moving average is $76.85 and its 200-day simple moving average is $70.67. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $91.96. The firm has a market capitalization of $33.92 billion, a P/E ratio of 35.53, a P/E/G ratio of 1.51 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.48 earnings per share. As a group, equities analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.